SAFETY AND PRELIMINARY EFFICACY FINDINGS FROM A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SETANAXIB IN PATIENTS WITH ALPORT SYNDROME

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/f4eb4314d287b2c50b16e1ca5ff8a3b5.pdf
SAFETY AND PRELIMINARY EFFICACY FINDINGS FROM A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SETANAXIB IN PATIENTS WITH ALPORT SYNDROME

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Daniel
Gale
Daniel Gale d.gale@ucl.ac.uk University College London Department of Renal Medicine London United Kingdom *
Irene Agraz Pamplona irene.agraz@vallhebron.cat Vall d'Hebron Institute of Research Vall d'Hebron Institute of Research Barcelona Spain -
Zainab Arslan Zainab.Arslan@gosh.nhs.uk Great Ormond Street Hospital for Children Department of Paediatric Nephrology London United Kingdom -
Rafael José Esteban de la Rosa rafaelj.esteban@gmail.com Hospital Universitario Virgen de las Nieves, and Instituto de Investigación Biosanitaria ibs.GRANADA Department of Nephrology Granada Spain -
Matthew Hall matthew.hall10@nhs.net Nottingham University Hospitals Nottingham Renal Unit Nottingham United Kingdom -
Karel Krejci Karel.Krejci@fnol.cz University Hospital and Faculty of Medicine Palacký University Olomouc 3rd Department of Internal Medicine – Nephrology, Rheumatology and Endocrinology Olomouc Czech Republic -
Enrique Morales emoralesr@senefro.org Hospital Universitario 12 de Octubre Department of Nephrology Madrid Spain -
Roman Safranek roman.safranek@fnhk.cz Charles University and University Hospital Hradec Kralove Medical Faculty Hradec Kralove Czech Republic -
Vladimir Tesar Vladimir.Tesar@vfn.cz General University Hospital, Charles University Department of Nephrology Prague Czech Republic -
Roser Torra rtorra@fundacio-puigvert.es Fundació Puigvert, Institut de Recerca Sant Pau (IR-Sant Pau), Departament de Medicina, Universitat Autònoma de Barcelona, RICORS2040 renal Nephrology Department Barcelona Spain -
Ondrej Viklicky onvi@ikem.cz Institute for Clinical and Experimental Medicine Department of Nephrology Prague Czech Republic -
Carl Stefan Carlsson stefan.carlsson@calliditas.com Calliditas Therapeutics AB Clinical Department Stockholm Sweden -
Aaron Levine aaron.levine@calliditas.com Calliditas Therapeutics AB Statistics Department Stockholm Sweden -
Rachel Lennon Rachel.Lennon@manchester.ac.uk Royal Manchester Children’s Hospital Department of Paediatric Nephrology Manchester United Kingdom -
-